Evidence map›Paper›PMID 42329295›Full record

ArticleWorld journal of urology2026

Novel 30-amp MOSES versus MOSES 2.0 pulse-modulation technologies for holmium laser enucleation of the prostate (HoLEP).

Hazem Elmansy, Ahmed Mousa, Amr Hodhod, Ruba Abdul Hadi, Hani Nour, Mohannad Alharbi, Mohamad Baker Berjaoui, Sara-Lynn Tayebi, Monica Morgan, Ricardo R Gonzalez and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hazem ElmansyHouston Methodist Hospital, Houston, TX, USA. hazem.mansy@rocketmail.com.
Ahmed MousaThunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Amr HodhodKing Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
Ruba Abdul HadiThunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Hani NourTheodor Bilharz Research Institute, Giza, Egypt.
Mohannad AlharbiQassim University, Buraydah, Qassim, Saudi Arabia.
Mohamad Baker BerjaouiUniversity of Toronto, Toronto, ON, Canada.
Sara-Lynn TayebiWestern University, London, ON, Canada.
Monica MorganHouston Methodist Hospital, Houston, TX, USA.
Ricardo R GonzalezHouston Methodist Hospital, Houston, TX, USA.
Ahmed S ZakariaThunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to compare early perioperative and functional outcomes of holmium laser enucleation of the prostate (HoLEP) performed with the 30-amp MOSES system and MOSES 2.0 technology.

methodsWe retrospectively compared 65 patients who underwent HoLEP with the 30-amp MOSES system and 210 with MOSES 2.0 between June 2023 and April 2025.Intraoperative and perioperative outcomes were collected and analyzed at 1, 3, and 6 months postoperatively.

resultsThe two groups had comparable preoperative characteristics, with median prostate volumes of 105 and 111 cc in the MOSES 2.0 and 30-amp MOSES groups, respectively (p = 0.22). Intraoperatively, the MOSES 2.0 group demonstrated an 8-minute shorter median enucleation time (p = 0.007), a 3-minute shorter median hemostasis time (p < 0.001), and lower energy use (75.7 vs. 92.1 kJ, p < 0.001). Additionally, MOSES 2.0 demonstrated superior enucleation efficiency compared to 30-amp MOSES (2.2 vs. 2 g/min, p = 0.047). Other operative parameters were comparable between the two groups. Both technologies achieved comparable successful same-day trial of void rates of 94% in the MOSES 2.0 group and 93.4% in the 30-amp MOSES group (p = 0.88). Postoperative functional outcomes, including IPSS, QoL, Qmax, PVR, and PSA, were comparable between groups up to 6 months of follow-up.

conclusionHoLEP with 30-amp MOSES technology is a safe and effective option for treating benign prostatic obstruction. Both MOSES systems support same-day discharge with comparable safety and functional outcomes. The 30-amp MOSES system may offer a practical alternative for institutions without a dedicated 50-amp power supply. Large randomized controlled trials with longer follow-up are warranted.

Indexed as

Lasers, Solid-StateLaser TherapyProstatectomyProstatic HyperplasiaAgedHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeBenign prostatic hyperplasiaLaser prostate surgeryMOSES technologyProstate

Identifiers

PMID42329295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.